Physician profile
Peter M Knapp
NPI 1013921709
$9,580.10
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $274 · 2021: $6,270 · 2022: $1,111 · 2023: $1,033 · 2024: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,704.23 | 2021-2023 | Interstim |
| Boston Scientific Corporation | $460.96 | 2019-2023 | Ams 700, Advance Xp, Ams 700 Cxr Rte Kit |
| Abbvie INC. | $304.16 | 2022-2023 | |
| Astellas Pharma US INC | $302.26 | 2019-2023 | Xtandi |
| Neotract INC. | $238.66 | 2019 | |
| Pfizer INC. | $210.38 | 2019-2023 | |
| Janssen Biotech, INC. | $160.74 | 2019-2024 | Erleada |
| Axonics, INC. | $115.56 | 2022-2023 | Axonics, Bulkamid |
| Coloplast Corp | $106.51 | 2022-2023 | Speedicath |
| Bayer Healthcare Pharmaceuticals INC. | $91.24 | 2019-2023 | |
| Tolmar Pharmaceuticals, INC. | $89.47 | 2021 | |
| Myovant Sciences INC. | $86.86 | 2021-2022 | |
| Advanced Accelerator Applications | $84.97 | 2020 | |
| Dendreon Pharmaceuticals LLC | $68.07 | 2019 | |
| Urogen Pharma, INC. | $59.21 | 2022-2023 | Jelmyto |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $51.74 | 2019-2023 | Xgeva |
| Laborie Medical Technologies Corp. | $47.99 | 2020-2023 | |
| Blue Earth Diagnostics | $47.28 | 2019 | |
| Abbott Laboratories | $44.94 | 2021 | |
| Antares Pharma, INC. | $42.36 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $28.95 | 2019-2020 | |
| Allergan, INC. | $28.02 | 2019 | |
| Tolmar, INC. | $27.53 | 2023 | |
| Travere Therapeutics, INC. | $22.44 | 2020 | |
| Alnylam Pharmaceuticals INC. | $21.79 | 2023 | Givlaari |
| Progenics Pharmaceuticals, INC. | $21.16 | 2023 | Pylarify |
| Endo Pharmaceuticals INC. | $19.99 | 2022 | |
| Telix Pharmaceuticals | $18.16 | 2023 | Illuccix |
| Mallinckrodt Hospital Products INC. | $16.13 | 2020 | |
| Cook Medical LLC | $16.03 | 2023 | Tornado |
| Foundation Medicine, INC. | $14.99 | 2023 | |
| Medtronic USA, INC. | $14.17 | 2019 | |
| Mission Pharmacal Company | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.